(“ArkBio”) announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a ...
Moderna’s top executives have sought to reassure investors they will be able to carry out the comeback plans announced in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback